Akili, a leading digital medicine firm, has unveiled a groundbreaking solution for adults with Attention Deficit Hyperactivity Disorder (ADHD). EndeavorOTC, an immersive mobile video game treatment, has been clinically proven to enhance attention and focus in individuals with ADHD.
This innovative technology, powered by Akili's unique Selective Stimulus Management Engine (SSME), builds upon the success of EndeavorRx, the first FDA-approved video game treatment for children aged eight to twelve with ADHD.
Recent clinical trial data revealed remarkable improvements in ADHD symptoms, concentration, focus, and overall quality of life in adults who used EndeavorOTC. Approximately 83% of participants reported clinical improvements in attention, while average focus levels improved by 85%.
In fact, over one-third of individuals experienced the elimination of attention deficits through this non-pharmacological treatment. Moreover, 73% of participants observed quality of life benefits, such as improved task management, timely completion of chores, and an enhanced ability to locate important items like keys and wallets.
The introduction of EndeavorOTC is particularly timely, as the COVID-19 pandemic has exacerbated mental health challenges and increased the demand for effective ADHD therapies.
Akili launched this groundbreaking solution under the FDA's enforcement policy, which expedites access to low-risk mental health digital health devices. By providing a safe and accessible non-drug option, EndeavorOTC addresses the gap between the growing demand for care and the limited availability of viable treatments for adults with ADHD.
This novel video game treatment signifies a significant step forward in ADHD therapy. Historically, adults with ADHD have been overlooked compared to children, despite the profound impact this condition can have on various aspects of their lives. Dr. Stephen Faraone, a Distinguished Professor, and Vice Chair for Research, highlights the adverse consequences of untreated ADHD on personal and professional well-being.
The President of the World Federation for ADHD emphasizes the urgent need for new, non-pharmacological treatments that effectively support adults with ADHD. EndeavorOTC addresses this unmet need by providing adults with a fun and engaging treatment option. By leveraging the power of video games, Akili empowers individuals with ADHD to take control of their symptoms and improve their cognitive abilities.
The company plans to actively involve users in product development, seeking their feedback to create future versions of the game that are more engaging, enjoyable, and effective.
The availability of EndeavorOTC is especially crucial for millions of Americans who lack reliable access to medication or adequate mental healthcare providers. Eddie Martucci, CEO of Akili, emphasizes the significance of offering patients better non-drug treatment options.
Drawing upon the success of EndeavorRx in children, Martucci highlights the positive impact of the core technology inside EndeavorOTC, which has already helped thousands of children with ADHD. With the introduction of EndeavorOTC, eligible adults now have rapid access to a clinically established treatment alternative.
By engaging users in activities that enhance focus while disregarding distractions, the treatments effectively improve attention and daily functioning. Therefore, Akili's EndeavorOTC marks a groundbreaking advancement in ADHD therapy for adults.
